Neuropeptide SP protects against colitis and linked anxiety-like behavior through the putative roles of gut microbiota and metabolite inositol

作者：Jing Lan, Jiaqi Wang, S. Q. Huang, Chenyu Li, Ziteng Deng, Zhihui null Hao, Yunfei Ma · 发表于：Nature Communications · 年份：2026 · DOI：10.1038/s41467-025-67904-0 · 被引用次数：10 · 研究领域：Neuropeptides and Animal Physiology、Gut microbiota and health、Gastrointestinal motility and disorders

The gut-brain axis links gut inflammation to psychiatric symptoms in inflammatory bowel disease (IBD), but the underlying mechanisms remain unclear. We demonstrate that neuropeptide substance P (SP) alleviated intestinal injury and behavioral disorders induced by dextran sodium sulfate in mice. SP mitigated hippocampal neuroinflammation and inhibited microglial activation and astrocyte loss. Furthermore, SP improved gut microbiome dysregulation, and its protective effects depended on the putative roles of microbiota. Notably, through modulating microbiota, SP dampened the NF-κB pathway in microglia, and increased GABAergic/Ca2+ signaling within astrocytes. SP elevated the microbiota-derived metabolite inositol. Supplementing inositol mimicked SP’s benefits and activated GABAergic signaling, while the inositol inhibitor reversed SP’s neuroprotective impacts, highlighting inositol’s indispensable role. Collectively, SP exerts beneficial effects via microbiota’s putative roles and inositol, involving the suppression of microglial NF-κB pathway while enhancing astrocytic GABAergic/Ca²⁺ signaling. Our findings underscore SP’s potential as a therapeutic intervention for these disorders in IBD. The high prevalence of anxiety in inflammatory bowel disease patients. Here, authors show SP alleviates colitis and anxiety-like behaviors via gut microbiota and inositol by blocking microglial NF-κB and enhancing astrocytic GABAergic/Ca²⁺ signaling.